Infinity Pharmaceuticals initiates Phase I study of cancer drug
The Phase I trial is an open-label, dose-escalation study evaluating IPI-926 in approximately 30 to 50 patients with advanced or metastatic solid tumors. The primary objectives of the
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).
Under the licensing agreement, Ono is responsible for developing and commercializing subcutaneous Relistor in Japan, including conducting the clinical development necessary to support regulatory marketing approval. Progenics will